Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 12/20 | 0.49 |
| ▸ | CDK2 | P24941 | 12/20 | 0.49 |
| ▸ | FLT3 | P36888 | 12/20 | 0.49 |
| ▸ | TYK2 | P29597 | 5/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17911314 | 1.00 | CCNE1 (0.49) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL16531917 | 0.87 | TYK2 (0.49) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL17911319 | 0.87 | TYK2 (0.49) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL16531926 | 0.85 | TYK2 (0.50) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL17911322 | 0.85 | TYK2 (0.50) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL3721030 | 0.85 | TYK2 (0.64) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL3721026 | 0.85 | TYK2 (0.64) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL16531907 | 0.84 | TYK2 (0.48) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL17911315 | 0.84 | TYK2 (0.48) | CCNE1CDK2FLT3TYK2KIT | |
| SCHEMBL3775723 | 0.83 | TYK2 (0.58) | CCNE1CDK2FLT3TYK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | claimed |
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015026574-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | AAK1, DAPK1, DAPK2 | CCNE1 4276/4885CDK2 768/4885FLT3 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.